The National Cancer Institute (NCI) requires that all NCI Designated Cancer Centers involved in clinical research have a mechanism for assuring adequate internal oversight of the scientific aspects of all cancer-related protocols at the institution. The Tisch Cancer Institute’s Protocol Review and Monitoring System (PRMS) serves as this mechanism and oversees all cancer-related clinical research studies across the Mount Sinai Health System.
The PRMS is responsible for the following:
- Conducting a thorough scientific and statistical review of all new protocols
- Reviewing the appropriateness of Data and Safety Monitoring Plans
- Ensuring the clinical research portfolio supports the research mission of The Tisch Cancer Institute
- Overseeing the appropriate prioritization of protocols
- Monitoring active protocols for ongoing scientific progressand accrual
- Closing protocols that do not meet accrual or scientific progress guidelines
The PRMS has the authority to open protocols that meet the scientific merit and priorities of The Tisch Cancer Institute, and to terminate protocols that do not demonstrate scientific progress.
All cancer-related clinical research studies at the Mount Sinai Health System are required to be reviewed and approved by the PRMS prior to submission to any Institutional Review Board.
Access our intranet site to review the PRMS Policies, Forms, and Meeting Schedules.